Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 2236-2244

  Yang, Hushan ^a   Gu, Jian ^a   Lin, Xin ^a   Grossman, H Barton ^a   Ye, Yuanqing ^a   Dinney, Colin P ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; CHROMOSOME PROTEIN; CYCLOOXYGENASE 2; INTERLEUKIN 4 RECEPTOR;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CYSTITIS; DISEASE ASSOCIATION; DNA FINGERPRINTING; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 42249092101     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1670     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Burin GJ, Gibb HJ, Hill RN. Human bladder cancer: evidence for a potential irritation-induced mechanism. Food Chem Toxicol 1995;33:785-95.
3. Wu X, Gu J, Grossman HB, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet 2006;78:464-79.
4. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59.
5. Whiteside TL. The role of immune cells in the tumor microenvironment. Cancer Treat Res 2006;130:103-24.
6. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-33.
7. American Cancer Society. Cancer facts and figures 2005. Atlanta (GA): American Cancer Society; 2005.
8. Bedwani R, Renganathan E, El Kwhsky F, et al. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer 1998;77:1186-9.
9. Kantor AF, Hartge P, Hoover RN, et al. Urinary tract infection and risk of bladder cancer. Am J Epidemiol 1984;119:510-5.
10. Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003;125:364-71.
11. Tsai FJ, Chang CH, Chen CC, et al. Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder. BJU Int 2005;95:432-5.
12. Bid HK, Manchanda PK, Mittal RD. Association of interleukin-1Ra gene polymorphism in patients with bladder cancer: case control study from North India. Urology 2006;67:1099-104.
13. Kang S, Kim YB, Kim MH, et al. Polymorphism in the nuclear factor κ-B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett 2005;217:11-6.
14. Leibovici D, Grossman HB, Dinney CP, et al. Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. J Clin Oncol 2005;23:5746-56.
15. Yue P, Melamud E, Moult J. SNPs3D: candidate gene and SNP selection for association studies. BMC Bioinformatics 2006;7:166.
16. Tobler AR, Short S, Andersen MR, et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. J Biomol Tech 2005;16:398-406.
17. Schmittgen TD, Jiang J, Liu Q, et al. A high-throughput method to monitor the expression of microRNA precursors. Nucleic Acids Res 2004;32:e43.
18. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
19. Wacholder S, Chanock S, Garcia-Closas M, et al. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
20. Hill DA, Wang SS, Cerhan JR, et al. Risk of non-Hodgkin lymphoma (NHL) in relation to germline variation in DNA repair and related genes. Blood 2006;108:3161-7.
21. Rothman N, Skibola CF, Wang SS, et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006;7:27-38.
22. Hung RJ, Brennan P, Canzian F, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 2005;97:567-76.
23. Matullo G, Guarrera S, Sacerdote C, et al. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev 2005;14:2569-78.
24. Romzova M, Hohenadel D, Kolostova K, et al. NFκB and its inhibitor IκB in relation to type 2 diabetes and its microvascular and atherosclerotic complications. Hum Immunol 2006;67:706-13.
25. Vohl MC, Lepage P, Gaudet D, et al. Molecular scanning of the human PPARα gene: association of the L162v mutation with hyperapobetalipoproteinemia. J Lipid Res 2000;41:945-52.
26. Flavell DM, Pineda Torra I, Jamshidi Y, et al. Variation in the PPARα gene is associated with altered function in vitro and plasma lipid concentrations in type II diabetic subjects. Diabetologia 2000;43:673-80.
27. Skogsberg J, Kannisto K, Cassel TN, et al. Evidence that peroxisome proliferator-activated receptor δ influences cholesterol metabolism in men. Arterioscler Thromb Vasc Biol 2003;23:637-43.
28. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998;20:284-7.
29. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor γ (hPPARγ) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ2 missense mutation. Biochem Biophys Res Commun 1997;241:270-4.
30. Kawashima T, Noguchi E, Arinami T, et al. Linkage and association of an interleukin 4 gene polymorphism with atopic dermatitis in Japanese families. J Med Genet 1998;35:502-4.
31. Suppiah V, Goris A, Alloza I, et al. Polymorphisms in the interleukin-4 and IL-4 receptor genes and multiple sclerosis: a study in Spanish-Basque, Northern Irish and Belgian populations. Int J Immunogenet 2005;32:383-8.
32. Hershey GK, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the α subunit of the interleukin-4 receptor. N Engl J Med 1997;337:1720-5.
33. Suarez A, Castro P, Alonso R, et al. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003;75:711-7.
34. Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir Res 2003;4:14.
35. Vladich FD, Brazille SM, Stern D, et al. IL-13 R130Q, a common variant associated with allergy and asthma, enhances effector mechanisms essential for human allergic inflammation. J Clin Invest 2005;115:747-54.
36. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun 1999;259:344-8.
37. Papafili A, Hill MR, Brull DJ, et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002;22:1631-6.
38. Chen YC, Giovannucci E, Lazarus R, et al. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005;65:11771-8.
39. Wild PJ, Kunz-Schughart LA, Stoehr R, et al. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 2005;27:385-91.
40. Abdullah L, Ait-Ghezala G, Crawford F, et al. The cyclooxygenase 2 -765 C promoter allele is a protective factor for Alzheimer's disease. Neurosci Lett 2006;395:240-3.
41. Ulrich CM, Whitton J, Yu JH, et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005;14:616-9.
42. Hu Z, Miao X, Ma H, et al. A common polymorphism in the 3′UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer 2005;48:11-7.
43. Park JM, Choi JE, Chae MH, et al. Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer 2006;6:70.
44. Langsenlehner U, Yazdani-Biuki B, Eder T, et al. The cyclooxygenase-2 (PTGS2) 8473T>C polymorphism is associated with breast cancer risk. Clin Cancer Res 2006;12:1392-4.
45. Dixon DA, Kaplan CD, McIntyre TM, et al. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3′-untranslated region. J Biol Chem 2000;275:11750-7.
46. Mohrenweiser HW, Wilson DM III, Jones IM. Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 2003;526:93-125.
47. Nelson MR, Kardia SL, Ferrell RE, et al. A combinatorial partitioning method to identify multilocus genotypic partitions that predict quantitative trait variation. Genome Res 2001;11:458-70.
48. Millikan RC, Hummer A, Begg C, et al. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis 2006;27:610-8.
49. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
50. Lan Q, Zheng T, Rothman N, et al. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 2006;107:4101-8.